Latest period
$14.26M
YoY change
+55.1%
5Y CAGR
+40.4%
Peak year (2025)
$15.99M
Cumulative CapEx
$61.51M
CapEx history chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: $15.99M
CapEx growth chart for Revolution Medicines (RVMD) from 2017 to 2025
Latest: +55.1%
CapEx history table for Revolution Medicines (RVMD) from 2017 to 2025
| 2025 | $15.99M | +55.1% | +$5.68M | ||
| 2024 | $10.31M | +33.4% | +$2.58M | ||
| 2023 | $7.73M | -28.5% | −$3.09M | ||
| 2022 | $10.82M | +65.7% | +$4.29M | ||
| 2021 | $6.53M | +122.6% | +$3.60M | ||
| 2020 | $2.93M | +13.3% | +$344.00K | ||
| 2019 | $2.59M | +72.7% | +$1.09M | ||
| 2018 | $1.50M | -4.8% | −$76.00K | ||
| 2017 | $1.57M | — | — |
- 2025$15.99M+55.1%
- 2024$10.31M+33.4%
- 2023$7.73M-28.5%
- 2022$10.82M+65.7%
- 2021$6.53M+122.6%
- 2020$2.93M+13.3%
- 2019$2.59M+72.7%
- 2018$1.50M-4.8%
- 2017$1.57M—
CapEx values are taken from Revolution Medicines's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About CapEx at Revolution Medicines (RVMD)
According to Revolution Medicines's latest reported financial statements, the company's current CapEx (TTM) is $14.26M. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Revolution Medicines (RVMD) CapEx is $15.99M – surged 55.1% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Revolution Medicines CapEx compounded at +40.4% per year, sustaining 2 straight years of year-over-year growth.
Across the available history, CapEx reached its high of $15.99M in 2025 and its low of $1.50M in 2018.
Revolution Medicines Capital Expenditures by Year
Revolution Medicines Capital Expenditures 2025: $15.99M
Revolution Medicines CapEx in 2025 was $15.99M, surged 55.1% from 2024. This figure represents the highest annual value in the available history.
Revolution Medicines Capital Expenditures 2024: $10.31M
2024's CapEx for Revolution Medicines came in at $10.31M, surged 33.4% from 2023.
Revolution Medicines Capital Expenditures 2023: $7.73M
Revolution Medicines posted CapEx of $7.73M in 2023, declined 28.5% below 2022.
Revolution Medicines Capital Expenditures 2022: $10.82M
In 2022, Revolution Medicines reported CapEx of $10.82M, surged 65.7% from 2021.
Revolution Medicines Capital Expenditures 2021: $6.53M
Revolution Medicines CapEx in 2021 was $6.53M.
See more financial history for Revolution Medicines (RVMD).
Sector peers by CapEx
Healthcare peers of Revolution Medicines (RVMD), ranked by their latest CapEx
| $14.05B | |
| $7.84B | |
| $5.91B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $1.86B | |
| $1.21B |
- $14.05B
- $7.84B
- $5.91B
- $4.83B
- $4.11B
- $3.62B
- $1.86B
- $1.21B
Frequently asked questions
Revolution Medicines (RVMD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation